UP!

AFFX $14.01   View long term graphs

Affymetrix, Inc.
Type
Subsidiary
Industry Biotechnology
Founded 1992
Headquarters Santa Clara, California, U.S.
High Wycombe, Buckinghamshire, UK
Tokyo, Japan
Shanghai, China
Number of locations
11
Key people
Stephen Fodor Frank Witney (CEO)
Revenue Increase US$327 Million (FY 2009)
Operating income
Decrease US$-30.6 Million (FY 2009)
Net income
Decrease US$-23.9 Million (FY 2009)
Total assets Decrease US$612 Million (FY 2009)
Total equity Decrease US$288 Million (FY 2009)
Number of employees
1,141
Parent Thermo Fisher Scientific
Website www.affymetrix.com

Affymetrix, Inc. was an American company that manufactured DNA microarrays; it was based in Santa Clara, California, United States. The company was acquired by Thermo Fisher Scientific in March 2016.

The company was founded by Dr. Stephen Fodor in 1992. It began as a unit in Affymax N.V. in 1991 by Fodor's group, which had in the late 1980s developed methods for fabricating DNA microarrays, called "GeneChip" according to the Affymetrix trademark, using semiconductor manufacturing techniques. The company's first product, an HIV genotyping GeneChip, was introduced in 1994 and the company went public in 1996. As a result of its pioneering work and the ensuing popularity of microarray products, Affymetrix derived significant benefit from its patent portfolio in this area.

Affymetrix acquired Genetic MicroSystems for slide-based microarrays and scanners, Neomorphic for bioinformatics, ParAllele Bioscience for custom SNP genotyping, USB/Anatrace for biochemical reagents, eBioscience for flow cytometry, and Panomics and True Materials to expand its offering of low to mid-plex applications. In 2000, Perlegen Sciences spun out from Affymetrix to focus on wafer-scale genomics for massive data creation and collection required for characterizing population variance of genomic markers and expression for the drug discovery process.

On January 8, 2016, Thermo Fisher Scientific announced the acquisition of Affymetrix for approximately $1.3 billion. The acquisition closed on March 31, 2016.

Affymetrix makes quartz chips for analysis of DNA Microarrays called GeneChip arrays. Affymetrix's GeneChip arrays assist researchers in quickly scanning for the presence of particular genes in a biological sample. Within this area, Affymetrix is focused on oligonucleotide microarrays. These microarrays are used to determine which genes exist in a sample by detecting specific pieces of mRNA. A single chip can be used to analyze thousands of genes in one assay. Chips can be used only once.

Affymetrix sells both mass-produced GeneChip arrays intended to match scientifically important parts of human and other animal genomes. Affymetrix manufactures its GeneChip arrays using photolithography. The company also manufactures machinery for high speed analysis of biological samples.

Affymetrix GeneChip Operating Software is a software system for managing Affymetrix microarray data.

Competitors in the DNA Microarray business include Illumina, GE Healthcare, Applied Biosystems, Beckman Coulter, Eppendorf Biochip Systems [1], and Agilent. There are also various inexpensive plastic-based technologies under development in small companies and laboratories around the world. It has been widely speculated that mass-produced plastic chips can be produced at lower prices than Affymetrix's quartz chips.

The Food and Drug Administration in January 2014 cleared a first-of-a-kind whole-genome postnatal blood test that can aid physicians in identifying the underlying genetic cause of developmental delay, intellectual disability, congenital anomalies, or dysmorphic features in children. This test, known as CytoScan Dx Assay, is designed to diagnose these disabilities earlier to expedite appropriate care and support. "About 2 to 3 percent of U.S. children have some sort of intellectual disability, according to the National Institutes of Health."

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2016 2016-07-31 Future report Set alerts
Q1 2016 2016-04-27 Future report Set alerts
Q4 2015 2016-02-17 0.09 0.05
Q3 2015 2015-10-28 0.10 -0.07
Q2 2015 2015-07-29 0.12 0.08
Q1 2015 2015-04-29 0.10 0.06
Q4 2014 2015-02-04 0.09 0.05
Q3 2014 2014-10-30 0.08 0.03
Q2 2014 2014-07-31 0.07 -0.01
Q1 2014 2014-05-01 0.03 -0.14

Ratings

2016-04-03 Reiterated Rating Cantor Fitzgerald Hold $14.00
2016-03-23 Reiterated Rating BTIG Research Neutral
2016-03-22 Reiterated Rating Cantor Fitzgerald Hold $14.00
2016-02-18 Reiterated Rating BTIG Research Neutral
2016-02-18 Boost Price Target Cowen and Company Market Perform $10.00 to $14.00
2016-01-25 Downgrade Cantor Fitzgerald Buy to Hold $13.00 to $14.00
2016-01-11 Downgrade Mizuho Buy to Neutral $14.00
2015-10-29 Reiterated Rating BTIG Research Hold
2015-10-06 Lower Price Target Cowen and Company $12.00 to $10.00
2015-08-27 Reiterated Rating Maxim Group Buy $13.00
2015-08-26 Initiated Coverage Cantor Fitzgerald Buy $13.00
2015-07-30 Reiterated Rating BTIG Research Neutral
2015-05-07 Reiterated Rating Mizuho Buy $14.00 to $15.00
2015-05-04 Reiterated Rating BTIG Research Neutral
2015-02-05 Upgrade JPMorgan Chase & Co. Underweight to Neutral $8.00 to $10.00
2015-02-05 Reiterated Rating BTIG Research Neutral
2015-01-21 Downgrade Robert W. Baird Outperform to Neutral $11.00
2015-01-12 Boost Price Target Mizuho Buy $12.00 to $14.00
2014-10-03 Initiated Coverage ING Group Neutral $7.50 to $10.00
2014-10-02 Initiated Coverage BTIG Research Neutral
2014-08-01 Boost Price Target Leerink Swann $7.50 to $9.00
2014-05-05 Boost Price Target Leerink Swann Market Perform $6.50 to $7.50
2014-05-02 Reiterated Rating Bank of America Underperform $7.00 to $7.50
2014-02-06 Reiterated UBS Neutral $7 to $9
2014-01-07 Boost Price Target Maxim Group Buy $9.00 to $11.00
2014-01-06 Downgrade Morgan Stanley Equal Weight to Underweight $7.20
2013-11-22 Boost Price Target Mizuho Buy $10.00 to $12.00
2013-10-31 Boost Price Target Mizuho Buy $8.00 to $10.00
2013-09-30 Boost Price Target Maxim Group Buy $6.00 to $8.00
2013-09-27 Boost Price Target Goldman Sachs Sell $3.70 to $4.00
2013-09-09 Reiterated Mizuho Buy $6 to $8
2013-02-01 Reiterated UBS Neutral $3.50 to $4
2012-03-15 Resumed Stifel Nicolaus Buy $19
2011-06-15 Resumed Wedbush Neutral $7
2011-06-02 Upgrade Robert W. Baird Neutral to Outperform $6 to $11
2011-03-17 Initiated Oppenheimer Perform
2010-10-28 Reiterated Deutsche Bank Hold $4.75 to $5
2010-10-12 Reiterated Deutsche Bank Hold $4.75 to $5
2010-07-13 Reiterated Deutsche Bank Hold $8 to $4.50
2010-07-08 Reiterated UBS Neutral $7 to $4.50
2010-02-04 Upgrade JP Morgan Underweight to Neutral
2010-01-13 Downgrade Barclays Capital Equal Weight to Underweight $6 to $3
2009-11-04 Upgrade Deutsche Securities Sell to Hold $6.50
2009-07-23 Upgrade Piper Jaffray Neutral to Overweight
2009-01-29 Downgrade JP Morgan Neutral to Underweight
2016-04-03 Reiterated Rating Cantor Fitzgerald Hold $14.00
2016-03-23 Reiterated Rating BTIG Research Neutral
2016-03-22 Reiterated Rating Cantor Fitzgerald Hold $14.00
2016-02-18 Reiterated Rating BTIG Research Neutral
2016-02-18 Boost Price Target Cowen and Company Market Perform $10.00 to $14.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In AFFX 2 funds of 2184 total. Show all

Fund name Ticker shares
Adamant Biomedical Investments AG 50000
VTL Associates, LLC 20024

Major Shareholders

Name Relationship Total Shares Holding stocks
King Kevin M President and CEO 0.37%  (271248) AFFX / IRTC /
FODOR STEPHEN P A 0.28%  (204116) AFFX /
BARABE TIMOTHY C Chief Financial Officer 0.23%  (166378) AFFX / ARQL / OPXA / VEEV /
DIEKMAN JOHN D 0.14%  (102998) AFFX /
RUNKEL JOHN F JR EVP and General Counsel 0.11%  (78296) AFFX / SNPS /
WAYMAN ROBERT PAUL 0.05%  (37392) AFFX / CFN /

Comments